Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
October 11, 2021
Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.
EU finds J&J COVID shot possibly linked to another rare clotting condition
October 4, 2021
EMA said the new, possibly life-threatening VTE condition to be included on the J&J product label was separate from TTS.
Doctors search for missing link between COVID-19 and ITP
January 28, 2021
“We don’t know much about platelet counts in COVID-19 at all.”
In COVID-19 patients, risk of bleeding rivals risk of thromboembolism
January 12, 2021
Trials are urgently needed to define optimal anticoagulation strategies for COVID-19 infection.
A 4-point thrombocytopenia score was found able to rule out suspected HIT
January 11, 2021
A low score – 3 points or less – has a negative predictive value of 99.8%, “so HIT is basically ruled out.”
Cost is the main hurdle to broad use of caplacizumab for TTP
December 7, 2020
“If we take finances out, I think almost every patient except those with a bleeding risk or bleeding problem should get it,” an investigator said.
INR fails to predict bleeding in patients with cirrhosis
October 6, 2020
The investigators hope the study findings reinforce minimizing administration of fresh frozen plasma for inappropriate correction of international normalized ratio, which carries a multitude of adverse effects among cirrhotic patients.
Pandemic strains blood supply for COVID-19 and noninfected patients
April 16, 2020
“There needs to be a significant call out for people to make every effort to donate blood.”
Updated international consensus recommendations on management of acute upper GI bleeding
October 21, 2019
Updated guidelines on management of nonvariceal acute upper GI bleeding address questions on endoscopic techniques and pharmacologic management.
Rivaroxaban tied to higher GI bleeding than other NOACs
June 17, 2019
SAN DIEGO – Real-world studies comparing the GI bleeding rates among different non–vitamin K anticoagulants have been limited.